Salix Pharmaceuticals Ltd (SLXP)

172.81
0.16 0.09
NASDAQ : Health Care
Prev Close 172.65
Open 172.72
Day Low/High 172.71 / 172.96
52 Wk Low/High 86.00 / 172.98
Volume 4.30M
Avg Volume 3.38M
Exchange NASDAQ
Shares Outstanding 64.25M
Market Cap 11.10B
EPS -6.53
P/E Ratio N/A
Div & Yield N.A. (N.A)
Salix Pharmaceuticals Completes Acquisition Of Santarus

Salix Pharmaceuticals Completes Acquisition Of Santarus

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has completed its previously announced tender offer for all outstanding shares of common stock par value $0.

Interesting SLXP Put And Call Options For February 2014

Interesting SLXP Put And Call Options For February 2014

Investors in Salix Pharmaceuticals Ltd saw new options become available this week, for the February 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SLXP options chain for the new February 2014 contracts and identified one put and one call contract of particular interest.

Salix Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Acquisition Of Santarus

Salix Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Acquisition Of Santarus

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix”) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) in connection with...

Our new retail holding Fifth & Pacific is a high performer

Our new retail holding Fifth & Pacific is a high performer

Fifth & Pacific's stock is rising on speculation it will sell off Lucky Brand business.

Salix Pharmaceuticals Commences Cash Tender Offer For All Outstanding Shares Of Santarus

Salix Pharmaceuticals Commences Cash Tender Offer For All Outstanding Shares Of Santarus

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix”) today announced the commencement of a cash tender offer by its indirect wholly owned subsidiary, Willow Acquisition Sub Corporation (“Purchaser”), to...

Investors Expect too Much of Salix

Investors Expect too Much of Salix

There are still too many unknowns about the pipeline to suggest there is further value here.

Salix Announces Approval Of Additional Injection Techniques For Deflux®

Salix Announces Approval Of Additional Injection Techniques For Deflux®

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has approved the Deflux ® premarket approval (PMA)...

New Lifetime High Today: Salix Pharmaceuticals (SLXP)

New Lifetime High Today: Salix Pharmaceuticals (SLXP)

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a new lifetime high candidate

Salix Pharmaceuticals Moves Up In Market Cap Rank, Passing Iron Mountain

Salix Pharmaceuticals Moves Up In Market Cap Rank, Passing Iron Mountain

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Salix Pharmaceuticals Ltd was identified as having a larger market cap than the smaller end of the S&P 500, for example Iron Mountain Inc , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

Buyer views target's diabetes and heartburn treatments as complementary to its drug lineup.

New Lifetime High Reached: Salix Pharmaceuticals (SLXP)

New Lifetime High Reached: Salix Pharmaceuticals (SLXP)

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a new lifetime high candidate

Salix Pharma to Acquire Santarus

Salix Pharma to Acquire Santarus

Salix Pharmaceuticals announced it will acquire Santarus in a deal worth $2.6 billion.

Salix Pharmaceuticals Reports 3Q2013 Results

Salix Pharmaceuticals Reports 3Q2013 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2013 and other business updates.

Salix Pharmaceuticals To Acquire Santarus

Salix Pharmaceuticals To Acquire Santarus

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Santarus, Inc.

Salix Pharmaceuticals Outlines Data Presentations At American Association For The Study Of Liver Diseases Annual Meeting

Salix Pharmaceuticals Outlines Data Presentations At American Association For The Study Of Liver Diseases Annual Meeting

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that presentations related to the investigation of rifaximin are scheduled to take place during the 64 th Annual Meeting of the American Association for the...

Salix Pharmaceuticals Announces 3Q2013 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 3Q2013 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report third quarter 2013 financial results following the close of the U.

Hedge Funds Are Buying 8 Rallying Healthcare Stocks Benefitting From Obamacare

Hedge Funds Are Buying 8 Rallying Healthcare Stocks Benefitting From Obamacare

Emily Smykal, Kapitall: The GOP may not be happy about it, but healthcare sure is - we found stocks benefitting [...]

Ulcerative Colitis For Dummies® Now Available Online

Ulcerative Colitis For Dummies® Now Available Online

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the availability of Ulcerative Colitis For Dummies®, Special Edition.

Salix Pharmaceuticals Outlines Data Presentations At American College Of Gastroenterology 2013 Annual Scientific Meeting

Salix Pharmaceuticals Outlines Data Presentations At American College Of Gastroenterology 2013 Annual Scientific Meeting

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that presentations related to the investigation of three of the Company’s products are scheduled to take place during the American College of ...

Salix And Progenics Announce FDA Advisory Committee Scheduled To Review Relistor SNDA For Opioid-Induced Constipation In Patients With Chronic Pain

Salix And Progenics Announce FDA Advisory Committee Scheduled To Review Relistor SNDA For Opioid-Induced Constipation In Patients With Chronic Pain

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ:PGNX) today announced that the FDA will convene an Advisory Committee on March 10-11, 2014 at which time Salix's Supplemental New Drug...

Salix Pharmaceuticals Previews PAINWeek® Presentation

Salix Pharmaceuticals Previews PAINWeek® Presentation

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that one poster presentation describing the investigation of methylnaltrexone bromide will occur during The National Conference on Pain for Frontline ...

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Drugs Laggard

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Drugs Laggard

Salix Pharmaceuticals was a leading decliner within the drugs industry, falling $1.32 (-1.9%) to $68.32 on average volume

Salix Pharmaceuticals Announces Call For Full Redemption Of Senior Convertible Notes

Salix Pharmaceuticals Announces Call For Full Redemption Of Senior Convertible Notes

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has notified the holders of the Company’s 5.

Salix Pharmaceuticals Reports 2Q2013 Results

Salix Pharmaceuticals Reports 2Q2013 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the second quarter ended June 30, 2013 and other business updates.

Salix Pharmaceuticals Announces 2Q2013 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 2Q2013 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report second quarter 2013 financial results following the close of the U.

Salix Stock Hits New 52-Week High (SLXP)

Salix Stock Hits New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Monday as it is currently trading at $69.78, above its previous 52-week high of $69.70 with 205,821 shares traded as of 12:01 p.m. ET. Average volume has been 595,700 shares over the past 30 days.

Expect Volatility Wednesday

The Fed's afternoon release of June 19 meeting notes may indicate the outlook for bond purchases and possibly members' fears about the market reaction.

Salix Reaches New 52-Week High (SLXP)

Salix Reaches New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Monday as it is currently trading at $68.71, above its previous 52-week high of $68.62 with 164,872 shares traded as of 11:26 a.m. ET. Average volume has been 577,700 shares over the past 30 days.

Salix Pharmaceuticals To Present At JMP Securities Healthcare Conference

Salix Pharmaceuticals To Present At JMP Securities Healthcare Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at The 8 th Annual JMP Securities Healthcare Conference in New York, NY on Wednesday, July 10, 2013 at 10:00 a.

Salix Rises On Unusually High Volume (SLXP)

Salix Rises On Unusually High Volume (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) is trading at unusually high volume Tuesday with one million shares changing hands. It is currently at two times its average daily volume and trading up $3.10 (+5%).